Jorge Alvar

Jorge Alvar

Auto-generated profile, based on publicly available information

Jorge Alvar

World Health Organization

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JAJorge Alvar
Jorge Alvar
IVIván D. Vélez
Iván D. Vélez
CBCaryn Bern
Caryn Bern
MHMercé Herrero
Mercé Herrero
PDPhilippe Desjeux
Philippe Desjeux
TTthe WHO Leishmaniasis Control Team
the WHO Leishmaniasis Control Team
As part of a World Health Organization-led effort to update the empirical evidence base for the leishmaniases, national experts provided leishmaniasis case data for the last 5 years and information regarding treatment and control in their respective countries and a comprehensive literature review was conducted covering publications on leishmaniasis in 98 countries and three territories (see ‘Leishmaniasis Country Profiles Text S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16, S17, S18, S19, S20, S21, S22, S23, S24, S25, S26, S27, S28, S29, S30, S31, S32, S33, S34, S35, S36, S37, S38, S39, S40, S41, S42, S43, S44, S45, S46, S47, S48, S49, S50, S51, S52, S53, S54, S55, S56, S57, S58, S59, S60, S61, S62, S63, S64, S65, S66, S67, S68, S69, S70, S71, S72, S73, S74, S75, S76, S77, S78, S79, S80, S81, S82, S83, S84, S85, S86, S87, S88, S89, S90, S91, S92, S93, S94, S95, S96, S97, S98, S99, S100, S101’). Additional information was collated during meetings conducted at WHO regional level between 2007 and 2011. Two questionnaires regarding epidemiology and drug access were completed by experts and national program managers. Visceral and cutaneous leishmaniasis incidence ranges were estimated by country and epidemiological region based on reported incidence, underreporting rates if available, and the judgment of national and international experts. Based on these estimates, approximately 0.2 to 0.4 cases and 0.7 to 1.2 million VL and CL cases, respectively, occur each year. More than 90% of global VL cases occur in six countries: India, Bangladesh, Sudan, South Sudan, Ethiopia and Brazil. Cutaneous leishmaniasis is more widely distributed, with about one-third of cases occurring in each of three epidemiological regions, the Americas, the Mediterranean basin, and western Asia from the Middle East to Central Asia. The ten countries with the highest estimated case counts, Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru, together account for 70 to 75% of global estimated CL incidence. Mortality data were extremely sparse and generally represent hospital-based deaths only. Using an overall case-fatality rate of 10%, we reach a tentative estimate of 20,000 to 40,000 leishmaniasis deaths per year. Although the information is very poor in a number of countries, this is the first in-depth exercise to better estimate the real impact of leishmaniasis. These data should help to define control strategies and reinforce leishmaniasis advocacy.

1 April 2008 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
JAJorge Alvar
Jorge Alvar
PAPilar Aparicio
Pilar Aparicio
AAAbraham Aseffa
Abraham Aseffa
MBMargriet Den Boer
Margriet Den Boer
CCCarmen CañaVate
Carmen CañaVate
JMJavier Moreno
Javier Moreno
SUMMARY: To date, most Leishmania and human immunodeficiency virus (HIV) coinfection cases reported to WHO come from Southern Europe. Up to the year 2001, nearly 2,000 cases of coinfection were identified, of which 90% were from Spain, Italy, France, and Portugal. However, these figures are misleading because they do not account for the large proportion of cases in many African and Asian countries that are missed due to a lack of diagnostic facilities and poor reporting systems. Most cases of coinfection in the Americas are reported in Brazil, where the incidence of leishmaniasis has spread in recent years due to overlap with major areas of HIV transmission. In some areas of Africa, the number of coinfection cases has increased dramatically due to social phenomena such as mass migration and wars. In northwest Ethiopia, up to 30% of all visceral leishmaniasis patients are also infected with HIV. In Asia, coinfections are increasingly being reported in India, which also has the highest global burden of leishmaniasis and a high rate of resistance to antimonial drugs. Based on the previous experience of 20 years of coinfection in Europe, this review focuses on the management of Leishmania-HIV-coinfected patients in low-income countries where leishmaniasis is endemic.

1 December 2006 in Trends in Parasitology
Verified
Journal Article
Closed access
JAJorge Alvar
Jorge Alvar
SYSergio Yactayo
Sergio Yactayo
CBCaryn Bern
Caryn Bern

1 October 2006 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
LSLouis D. Saravolatz
Louis D. Saravolatz
CBCaryn Bern
Caryn Bern
JAJill Adler-Moore
Jill Adler-Moore
JBJuan Berenguer
Juan Berenguer
MBMarleen Boelaert
Marleen Boelaert
JAJorge Alvar
Jorge Alvar
During the past decade, liposomal amphotericin B has been used with increasing frequency to treat visceral leishmaniasis (VL). The World Health Organ

1 October 2011 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PDF file
MBM. Den Boer
M. Den Boer
DAD. Argaw
D. Argaw
JJJ. Jannin
J. Jannin
JAJ. Alvar
J. Alvar

1 August 2007 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
JAJorge Alvar
Jorge Alvar
SBSeife Bashaye
Seife Bashaye
DADaniel Argaw
Daniel Argaw
ICIsra CRUZ
Isra CRUZ
PAPilar Aparicio
Pilar Aparicio
CBCaryn Bern
Caryn Bern
In May 2005, visceral leishmaniasis (VL) was recognized for the first time in Libo Kemkem, Ethiopia. In October 2005, a rapid assessment was conducted using data from 492 patients with VL treated in the district health center and a household survey of 584 residents of four villages. One subdistrict accounted for 71% of early cases, but the incidence and number of affected subdistricts increased progressively throughout 2004–2005. In household-based data, we identified 9 treated VL cases, 12 current untreated cases, and 19 deaths attributable to VL (cumulative incidence, 7%). Thirty percent of participants were leishmanin skin test positive (men, 34%; women, 26%; P = 0.06). VL was more common in men than women (9.7% versus 4.5%, P < 0.05), possibly reflecting male outdoor sleeping habits. Molecular typing in splenic aspirates showed L. infantum (six) and L. donovani (one). Local transmission resulted from multiple introductions, is now well established, and will be difficult to eradicate.